Antibody-Drug Conjugates (ADC) Preparation Research Reagents (577)

ADC drugs are targeted therapies created by linking monoclonal antibodies to small molecule toxin drugs via specialized linkers. They are composed of three key components: antibodies, small molecule toxins, and linkers, each with specific requirements. The antibody must exhibit high specificity and low immunogenicity, the linker must remain stable in the circulatory system while effectively releasing cytotoxins in the tumor microenvironment, and the small molecule toxin must be physiologically stable with potent tumor cell lethality. An ideal ADC drug should maintain stability in blood circulation, precisely target the treatment site, and release cytotoxic agents near the target area.